Company announces positive results from Phase 3 Trial of investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% for bacterial vaginosis
The DARE-BVFREE trial (n=307) met its primary endpoint demonstrating a single vaginally-administered dose of the hydrogel was superior to placebo at the time of cure visit 21 to 30 days after study drug administration.
Source:
Biospace Inc.